Cetuximab (Erbitux, C225)

DRUG2 trials

Sponsors

University of Pittsburgh, Sun Yat-sen University

Conditions

Colorectal Cancer MetastaticMalignant Solid Tumour

Phase 1

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

CompletedNCT00388427

University of PittsburghMalignant Solid Tumour

Start: 2007-06-30End: 2013-02-28Updated: 2015-05-28

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

RecruitingNCT07012954

Sun Yat-sen UniversityColorectal Cancer Metastatic

Start: 2025-06-01End: 2030-12-31Target: 64Updated: 2025-06-24